Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609402 | 1.00 | SLC6A2 (0.61) | SLC6A2SLC6A3OPRK1KCNH2OPRM1 | |
| SCHEMBL3601724 | 1.00 | SLC6A2 (0.61) | SLC6A2SLC6A3OPRK1KCNH2OPRM1 | |
| Hydrochloric Acid SCHEMBL4237024 | 0.99 | SLC6A2 (0.60) | SLC6A2SLC6A3OPRK1KCNH2OPRM1 | |
| Hydrochloric Acid SCHEMBL4237021 | 0.99 | SLC6A2 (0.60) | SLC6A2SLC6A3OPRK1KCNH2OPRM1 | |
| Hydrochloric Acid SCHEMBL4932113 | 0.97 | SLC6A2 (0.58) | SLC6A2SLC6A3OPRK1KCNH2OPRM1 | |
| SCHEMBL13849623 | 0.87 | SLC6A2 (0.63) | SLC6A2SLC6A3OPRK1KCNH2OPRM1 | |
| Hydrochloric Acid SCHEMBL4932120 | 0.84 | OPRK1 (0.56) | SLC6A2SLC6A3OPRK1KCNH2OPRM1 | |
| SCHEMBL4228503 | 0.84 | SLC6A2 (0.58) | SLC6A2SLC6A3OPRK1KCNH2OPRM1 | |
| SCHEMBL4228506 | 0.84 | SLC6A2 (0.58) | SLC6A2SLC6A3OPRK1KCNH2OPRM1 | |
| SCHEMBL14468236 | 0.82 | SLC6A2 (0.69) | SLC6A2SLC6A3OPRK1KCNH2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| EP-2121703-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008020799-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | SLC6A2 1701/4885SLC6A3 839/4885OPRK1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.